+

WO2018151347A1 - Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant - Google Patents

Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant Download PDF

Info

Publication number
WO2018151347A1
WO2018151347A1 PCT/KR2017/001705 KR2017001705W WO2018151347A1 WO 2018151347 A1 WO2018151347 A1 WO 2018151347A1 KR 2017001705 W KR2017001705 W KR 2017001705W WO 2018151347 A1 WO2018151347 A1 WO 2018151347A1
Authority
WO
WIPO (PCT)
Prior art keywords
threonine
cobb
protein
microorganism
gene
Prior art date
Application number
PCT/KR2017/001705
Other languages
English (en)
Korean (ko)
Inventor
정기용
조승현
손승주
이광호
이지선
Original Assignee
씨제이제일제당(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨제이제일제당(주) filed Critical 씨제이제일제당(주)
Priority to PCT/KR2017/001705 priority Critical patent/WO2018151347A1/fr
Publication of WO2018151347A1 publication Critical patent/WO2018151347A1/fr

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Definitions

  • the present invention relates to a microorganism having L-threonine production capacity, and a method for producing L-threonine using the same.
  • L-threonine is an amino acid widely used as feed additives, pharmaceutical raw materials or food raw materials, and is produced in large quantities by fermentation methods using microorganisms.
  • a target substance specific approach such as increasing expression of a gene encoding an enzyme involved in the generation of a target substance or removing a gene for which expression is unnecessary is mainly used.
  • energy in the form of NADH, NADPH and Adenosine-5'-triphosphate (ATP) in vivo is necessary because of the production and maintenance of sufficient energy for high yield production of the desired substance.
  • NAD NAD
  • Methods of strengthening by attenuation or deletion are known (Metabolic Engineering, 2002, 4, 238-247).
  • CobB is known that a denitration oxidase or talsuk Xin enzyme, are known to make up a second oxidized lysine and a complex of histone H4 protein, Zn 2 + binding site is present (J Mol Biol, 2004, 337 (3) 731-41).
  • the present inventors have tried to increase the NAD (H) required for the biosynthesis of a useful target substance such as L-amino acid, and thus discovered a cobB gene and manipulated the gene to improve the yield of L-threonine.
  • the present invention was completed by discovering that it can increase.
  • One object of the present invention is to provide a microorganism having L-threonine production capacity.
  • Another object of the present invention is to provide a method for producing L-threonine by using the microorganism having the L-threonine production capacity.
  • the present invention provides a microorganism having an L-threonine production capacity in which the activity of the CobB protein is inactivated compared to the intrinsic activity.
  • the term "CobB protein” may mean a protein lysine deacetylase and / or lysine desuccinylase, NAD (H) during the deoxidation reaction or desuccinization reaction May refer to a class III sirtuin protein using as a cofactor.
  • the CobB may include an enzyme having a similar activity, even if the enzyme has a different name, for example, an enzyme of the genus Escherichia .
  • the CobB protein may include the amino acid sequence of SEQ ID NO: 1.
  • the CobB protein may be a protein having a sequence homology of at least 70%, at least 80%, at least 90%, or at least 95% with the amino acid sequence of SEQ ID NO: 1.
  • the CobB protein is a sequence having such homology, and includes without limitation so long as it exhibits substantially the same or corresponding function as each protein.
  • the CobB protein is understood to include an amino acid sequence in which some amino acid sequences are deleted, modified, substituted or added as compared to the wild type CobB protein.
  • the gene encoding the CobB protein of the present invention may be to encode an amino acid sequence of SEQ ID NO: 1 and the amino acid sequence having a sequence homology of 70% or more, 80% or more, 90% or more, or 95% or more thereof.
  • the cobB gene may have a sequence homology of at least 70%, at least 80%, at least 90%, or at least 95% with the nucleotide sequence of SEQ ID NO: 2.
  • the cobB gene may be included without limitation so long as it encodes a protein exhibiting the same or corresponding function as the CobB protein.
  • a gene having such homology includes a gene in which some nucleotide sequences are deleted, modified, substituted or added as compared to the wild type cobB gene.
  • homology refers to a similar degree of nucleotide sequence or amino acid sequence of a gene encoding a protein. That is, the percentage of identity between two polynucleotide or polypeptide moieties. Homology between sequences from one moiety to another may be determined by techniques known in the art. For example, homology can be determined by aligning sequence information and directly aligning sequence information between two polynucleotide molecules or two polypeptide molecules using readily available computer programs.
  • the computer program may be BLAST (NCBI), CLC Main Workbench (CLC bio), MegAlign TM (DNASTAR Inc), or the like.
  • homology between polynucleotides can be determined by hybridizing polynucleotides under conditions of stable double stranding between homologous regions, followed by digestion with single-strand-specific nucleases to determine the size of the digested fragments.
  • intrinsic activity refers to the level of activity of a protein in its native state or in its natural state before it is modified.
  • the term “protein inactivated compared to endogenous activity” means that the protein mentioned in the microorganism is not expressed at all, or does not have any activity even when expressed, or the activity of the protein is weakened or eliminated compared to the endogenous activity. It means.
  • the term “attenuation” or “removal” of protein activity means that the expression of the gene encoding the protein is reduced or less than the intrinsic level.
  • a method of inactivating the activity of the protein a method of replacing a gene encoding the protein on a chromosome with a mutated gene such that the activity of the protein is reduced or absent; Introducing a mutation into an expression control sequence of a gene on a chromosome encoding said protein; Replacing the expression control sequence of the gene encoding the protein with a sequence having weak or no activity; Deleting all or part of a gene on a chromosome that encodes the protein; Introducing an antisense oligonucleotide (eg, antisense RNA) that complementarily binds to a transcript of a gene on the chromosome to inhibit translation from the mRNA to a protein; How to make the secondary structure impossible by attaching the complementary sequence to the SD sequence in front of the SD (Shine-Dalgarno) sequence of the gene encoding the protein to form a secondary structure and the ORF (open reading frame of the sequence)
  • a method of deleting part or all of a gene encoding a protein includes a polynucleotide or a marker in which a polynucleotide encoding an endogenous target protein in a chromosome through a bacterial chromosomal insertion vector is deleted in part or in entire nucleotide sequence thereof.
  • a method of deleting part or all of such genes a method of deleting genes by homologous recombination may be used.
  • the term "some" may vary depending on the type of polynucleotide, but may be, for example, 1 to 700, 1 to 500, 1 to 300, 1 to 100, or 1 to 50 nucleotides.
  • homologous recombination refers to genetic recombination occurring through linkage exchange at the locus of gene chains having homology with each other.
  • the protein was inactivated by homologous recombination.
  • the method of modifying an expression control sequence is carried out by inducing a mutation in the expression control sequence by deletion, insertion, non-conservative or conservative substitution, or a combination thereof in the nucleotide sequence of the expression control sequence, or by replacing with a weaker promoter.
  • the expression control sequence may include a promoter, an operator sequence, a sequence encoding a ribosomal binding site, and a sequence that controls the termination of transcription and translation.
  • a method of modifying a gene sequence on a chromosome may be performed by inducing a mutation in the sequence by deleting, inserting, non-conservative or conservative substitution, or a combination thereof, to further reduce the activity of the protein, or performing weaker activity. It can be carried out by replacing with a gene sequence that has been improved to have or a gene sequence that has been improved so that there is no activity.
  • microorganisms producing L-threonine or “microorganisms having L-threonine production capacity” refers to a microorganism or L-threonine which naturally has L-threonine production capacity. It refers to a microorganism to which the production capacity of threonine is given to a natural strain having no production capacity.
  • microorganisms having L-threonine producing ability may include all microorganisms producing L-threonine in which the activity of CobB protein of the present invention can be inactivated.
  • examples include Escherichia (Escherichia), An air Winiah (Erwinia) genus, Serratia marcescens (Serratia) genus, Providencia (Providencia) genus Corynebacterium (Corynebacterium) in and Brevibacterium genus Solarium (Brevibacterium) It may be a microorganism, but is not limited thereto.
  • the microorganism having the L-threonine production capacity of the present invention may be a microorganism of the genus Escherichia , more specifically, E. coli .
  • the present invention provides a method of preparing a culture medium comprising the steps of culturing an Escherichia spp. It provides a method for producing L-threonine comprising the step of obtaining L-threonine from the microorganism or the medium.
  • microorganism having the L-threonine production capacity or the Escherichia genus microorganism having the L-threonine production capacity is as described above.
  • the culture can be made according to the appropriate medium and culture conditions known in the art. Those skilled in the art can also easily adjust the medium and culture conditions. Specifically, the culture may be continuously cultured in a batch process, an injection batch or a repeated fed batch process, but is not limited thereto.
  • sugar sources that can be used include sugars and carbohydrates such as glucose, sucrose, lactose, fructose, maltose, starch, cellulose, oils and fats such as soybean oil, sunflower oil, castor oil, coconut oil, palmitic acid, stearic acid, Fatty acids such as linoleic acid, glycerol, alcohols such as ethanol, gluconic acid, acetic acid, organic acids such as pyruvic acid may be included, but are not limited thereto. These materials can be used individually or as a mixture.
  • Nitrogen sources that may be used may include peptone, yeast extract, gravy, malt extract, corn steep liquor, soybean wheat and urea or inorganic compounds such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, It is not limited to this. Nitrogen sources can also be used individually or as a mixture. Personnel that may be used may include, but are not limited to, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts.
  • the culture medium may contain a metal salt such as magnesium sulfate or iron sulfate required for growth. In addition to these substances, essential growth substances such as amino acids and vitamins can be used.
  • precursors suitable for the culture medium may be used, but are not limited thereto. The above-mentioned raw materials may be added batchwise or continuously by a suitable method to the culture medium during the culturing process.
  • Basic compounds such as sodium hydroxide, potassium hydroxide, ammonia or acid compounds such as phosphoric acid or sulfuric acid can be used in an appropriate manner to adjust the pH of the culture.
  • antifoaming agents such as fatty acid polyglycol esters can be used to inhibit bubble generation.
  • Oxygen or an oxygen-containing gas eg, air
  • the temperature of the culture may be usually 20 °C to 45 °C, for example 25 °C to 40 °C, or 30 °C to 40 °C.
  • the incubation period can last until the desired amount of L-threonine is obtained, for example 10 to 160 hours, or 10 to 72 hours.
  • L-threonine may be excreted in the culture medium or contained in cells.
  • Obtaining L-threonine of the present invention may include the step of separating and obtaining L-threonine from the microorganism or the medium, specifically, the culture medium or culture from which the cultured microorganism or microbial cells have been removed. Can be.
  • the separation and obtaining method may be obtained by separating L-threonine produced from the culture medium or whole culture from which microorganisms or microbial cells have been removed using a suitable method known in the art according to the culture method.
  • the separating may include a purification process.
  • microorganisms having L-threonine production inactivated CobB protein activity compared to the intrinsic activity of the present invention increases the level of intracellular NAD (H), resulting in high efficiency and high yield of L-threonine. Can produce.
  • 1 is a view showing the intracellular NAD (H) level of a strain having L- threonine production capacity according to one embodiment.
  • Figure 2 is a view showing the intracellular NAD (H) level of the strain having L- threonine production capacity according to one embodiment.
  • cobB gene from the E. coli W3110 ATCC 39936
  • wild-type E. coli strain homologous recombination was produced in a strain with a cobB gene deletion.
  • the cobB gene in E. coli is known to encode CobB proteins with protein lysine deacetylase activity and / or protein lysine desuccinylase activity.
  • the cobB to be deleted The gene has the nucleotide sequence of SEQ ID NO: 2.
  • the chloramphenicol gene of pUCprmfmloxP a marker for confirming insertion into the gene, was prepared as follows.
  • the chromosomal DNA (gDNA) of E. coli W3110 was extracted using a Genomic-tip system (Qiagen, Germany), and the gDNA was used as a template, and SEQ ID NO: 3 and A polymerase chain reaction (PCR) was carried out using the polynucleotide of 4 as a primer.
  • PCR to amplify the above 30 cycles consisting of 30 seconds denaturation at 94 °C, 30 seconds annealing (55 °C), and elongation of 2 minutes 30 seconds at 72 °C.
  • the obtained PCR product was digested with KpnI and EcoRV, electrophoresed on 0.8% agarose gel, and eluted to yield 0.3Kb Prmf fragment.
  • Prmf fragment and pUC19 New England Biolabs, USA
  • restriction enzymes KpnI and SmaI respectively, to prepare a pUC-Prmf plasmid.
  • a vector pUCprmfmloxP having a mutant loxP-CmR-loxP cassette and a promoter of the rmf gene at the same time the pACYC184 plasmid (New England Biolab, USA) (Accession Number X06403) was used as a template.
  • PCR was repeated for 30 cycles consisting of 30 seconds of denaturation at 94 ° C., 30 seconds of annealing at 55 ° C., and 1 minute elongation at 72 ° C. to obtain 1.1 kb of PCR product.
  • Secondary PCR was performed by using a primer combination of SEQ ID NOS: 9 and 10 containing 20 bp sequences of the 5 'and 3' regions of the PCR product obtained in the primary PCR, using the eluted primary PCR product as a template.
  • the secondary PCR product of about 1.3 kb was obtained by a secondary polymerase chain reaction of 30 cycles consisting of denaturation at 94 ° C for 30 seconds, annealing at 55 ° C for 30 seconds, and extension at 72 ° C for 1 minute. .
  • the secondary PCR product obtained was eluted after electrophoresis on 0.8% agarose gel and used for recombination.
  • E. coli W3110 (hereinafter referred to as 'pKD46-induced E. coli W3110') transformed with a pKD46 vector (Accession Number AY048746) according to a one-step inactivation method developed by Datsenko KA et al.
  • the secondary PCR product was introduced into pKD46-induced Escherichia coli W3110 by electroporation.
  • the secondary PCR product and pKD46-induced Escherichia coli W3110 were cultured in LB medium containing chloramphenicol to select a primary recombinant strain having chloramphenicol resistance.
  • the pKD64 vector was removed from the recombinant strain. Then, the pJW168 vector carrying the Cre-recombinase gene (Gene, (2000) 247,255-264) was introduced into the recombinant strain from which the pKD64 vector was removed, and the pJW168 vector was added to express Cre-recombinase from the introduced pJW168 vector. The introduced recombinant strain was incubated at 30 ° C. in LB medium containing ampicillin.
  • strains were selected by smearing isopropyl- ⁇ -D-1-thiogalactopyranoside (Isopropyl- ⁇ -D-1-thiogalactopyranoside: IPTG) on the medium.
  • Selected strains were genetic recombination at the mutant loxP position by Cre-recombinase to remove the chloramphenicol marker gene.
  • the strain from which the chloramphenicol marker gene was removed was cultured at 42 ° C. to remove the pJW168 vector, and finally, the obtained strain was named W3110_ ⁇ cobB .
  • cobB by about 0.5 kb PCR product obtained by PCR using the primers of SEQ ID NOs: 11 and 12 It was confirmed that the gene was deleted.
  • KCCM Culture Center microorganisms
  • pACYC184-thrABC vector was prepared to confirm the deletion effect of cobB in strains with enhanced threonine metabolic pathways, and this vector was introduced into the W3110_ ⁇ cobB strain prepared in Example 1 to W3110_ ⁇ cobB / pACYC184-thrABC was produced.
  • the vector pACYC184-thrABC was produced by the following method. Using the genomic DNA of Escherichia coli KCCM 10541 (Korean Patent Registration No. 10-0576342), a strain for producing L-threonine, as a template, a PCR reaction was performed using polynucleotides of SEQ ID NOs: 13 and 14 as primers, The obtained DNA fragment was separated and purified, digested with HindIII enzyme, and purified again to prepare a thrABC DNA fragment. The pACYC184 vector was digested with HindIII enzyme, purified and prepared, and ligated with the thrABC DNA fragment to prepare a pACYC184-thrABC vector.
  • the vectors thus prepared were introduced into the W3110 and W3110_ ⁇ cobB strains by electroporation and named W3110 / pACYC184-thrABC and W3110_ ⁇ cobB / pACYC184-thrABC, respectively.
  • cobB deletion strains were prepared from threonine producing strains in the same manner as in Example 1 using KCCM10541 (Korean Patent Registration No. 10-0576342), which is a threonine producing Escherichia coli, as a parent strain. It was named KCCM10541_ ⁇ cobB .
  • Example 1 The recombinant microorganisms prepared in Examples 1 and 2 of Example 1 were cultured in a 250 ml Erlenmeyer flask using the threonine titer medium of Table 1 to confirm the improvement of L-threonine productivity.
  • the parent strain W3110 did not produce any L-threonine when incubated for 48 hours, but the W3110_ ⁇ cobB strain produced 0.01 g / L of L-threonine in a small amount. It was.
  • the strain W3110 / pACYC184-thrABC which enhanced the threonine biosynthesis pathway, produced 1.42 g / L of threonine, whereas the strain W3110_ ⁇ cobB / pACYC184-thrABC produced 1.89 g / L of threonine. It was confirmed that the produced threonine concentration was increased by 33%.
  • intracellular NAD (H) levels were measured using strain W3110_ ⁇ cobB prepared in Example 1-1.
  • the NAD / NADH measurement kit EnzyChrom TM NAD + / NADH Assay Kit (ECND-100) developed by Bioassay systems was used (Mol Cancer Ther., 2008, 7 (1): 110-120).
  • W3110 and W3110_ ⁇ cobB of Example 1 were incubated overnight in the LB liquid medium containing glucose used in Example 1 of 1 contained in 250 ml of Erlenmeyer flasks. After incubation, the supernatant was removed by centrifugation, and the obtained cells were washed with ice-cold PBS, and treated with NADH / NAD extraction buffer (Permeable buffer) at room temperature and low temperature for 10 minutes and stirred to carry out NAD (H) in cells.
  • NADH / NAD extraction buffer Permeable buffer
  • Example 3 In order to measure the threonine production titers of KCCM10541_ ⁇ cobB , the cobB gene deletion strain prepared in Example 3, and the parent strain KCCM10541, the threonine yield was measured in the same manner as in Example 1-1.
  • Example 3 In order to evaluate the intracellular NAD (H) level of KCCM10541_ ⁇ cobB , the cobB gene deletion strain prepared in Example 3, and the parent strain KCCM10541, the NAD (H) level was measured in the same manner as in Example 2-2. Measured.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente invention concerne un microorganisme ayant un potentiel de production de L-thréonine et une méthode de production de L-thréonine l'utilisant.
PCT/KR2017/001705 2017-02-16 2017-02-16 Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant WO2018151347A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2017/001705 WO2018151347A1 (fr) 2017-02-16 2017-02-16 Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2017/001705 WO2018151347A1 (fr) 2017-02-16 2017-02-16 Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant

Publications (1)

Publication Number Publication Date
WO2018151347A1 true WO2018151347A1 (fr) 2018-08-23

Family

ID=63170698

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/001705 WO2018151347A1 (fr) 2017-02-16 2017-02-16 Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant

Country Status (1)

Country Link
WO (1) WO2018151347A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101261147B1 (ko) * 2011-01-18 2013-05-06 씨제이제일제당 (주) Ｌ-아미노산의 생산능이 향상된 미생물 및 이를 이용하여 ｌ-아미노산을 생산하는 방법
KR20170044523A (ko) * 2015-10-15 2017-04-25 씨제이제일제당 (주) L-쓰레오닌 생산능을 가지는 미생물 및 그를 이용하여 l-쓰레오닌을 생산하는 방법

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101261147B1 (ko) * 2011-01-18 2013-05-06 씨제이제일제당 (주) Ｌ-아미노산의 생산능이 향상된 미생물 및 이를 이용하여 ｌ-아미노산을 생산하는 방법
KR20170044523A (ko) * 2015-10-15 2017-04-25 씨제이제일제당 (주) L-쓰레오닌 생산능을 가지는 미생물 및 그를 이용하여 l-쓰레오닌을 생산하는 방법

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ABOUELFETOUH, ALAA: "The E. coli sirtuin CobB shows no preference for enzymatic and nonenzymatic lysine acetylation substrate sites", MICROBIOLOGYOPEN, vol. 1, 22 November 2014 (2014-11-22), pages 66 - 83, XP055375748 *
CASTANO-CEREZO, SARA: "Regulation of acetate metabolism in Escherichia coli BL21 by protein N( epsilon )-lysine acetylation", APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, vol. 99, 20 December 2014 (2014-12-20), pages 3533 - 3545, XP035475438 *
LI, RU: "CobB regulates Escherichia coli chemotaxis by deacetylating the response regulator CheY", MOLECULAR MICROBIOLOG Y, vol. 76, no. 5, 2010, pages 1162 - 1174, XP055375746 *
SANDMEIER, JOSEPH J.: "Telomeric and rDNA silencing in Saccharomyces cerevisiae are dependent on a nuclear NAD(+) salvage pathway", GENETICS, vol. 0, 16 March 2002 (2002-03-16), pages 877 - 889, XP055375751 *
YADAV, GHANSHYAM S.: "Phosphorylation modulates catalytic activity of mycobacterial sirtuins", FRONTIERS IN MICROBIOLOGY, vol. 7, no. 677, 9 May 2016 (2016-05-09), pages 1 - 13, XP055536995 *

Similar Documents

Publication Publication Date Title
KR101261147B1 (ko) Ｌ-아미노산의 생산능이 향상된 미생물 및 이를 이용하여 ｌ-아미노산을 생산하는 방법
WO2021162189A1 (fr) Souche mutante de corynébactérium glutamicum présentant une capacité de production améliorée d'acide l-glutamique et procédé de production d'acide l-glutamique l'utilisant
WO2012008809A2 (fr) Micro-organisme ayant une productivité de l-ornithine améliorée, et procédé pour produire de la l-ornithine en utilisant celui-ci
WO2016171392A1 (fr) Variant de répresseur de gluconate, micro-organisme producteur de l-lysine comprenant celui-ci et procédé de production de l-lysine faisant appel à celui-ci
WO2017034164A1 (fr) Micro-organisme corynebacterium sp. capable de produire de la l-lysine et procédé de production de l-lysine l'utilisant
WO2015199406A1 (fr) Micro-organisme de l'espèce escherichia à capacité de production de l-tryptophane et procédé de production de l-tryptophane au moyen de celui-ci
WO2015178586A1 (fr) Microorganisme présentant niveau d'énergie intracellulaire amélioré et procédé de production d'acides aminés l à l'aide de ce microorganisme
WO2015174655A1 (fr) Micro-organisme du genre corynebacterium pour produire une l-lysine et procédé de production de l-lysine au moyen du micro-organisme
WO2016182321A1 (fr) Micro-organismes du genre escherichia ayant une capacité de production de l-tryptophane et procédé de production de l-tryptophane à l'aide de ceux-ci
WO2017069567A1 (fr) Micro-organisme recombiné pour la production de l-thréonine et procédé de production de l-thréonine l'utilisant
KR102303662B1 (ko) 화합물을 생산하는 미생물 및 이를 이용한 화합물의 생산 방법
WO2017065529A1 (fr) Variant de l'o-acétylhomosérine sulfhydrylase et procédé de production de l-méthionine l'utilisant
WO2017065457A1 (fr) Microorganisme capable de produire de la l-thréonine et procédé de production de l-thréonine à l'aide de ce dernier
WO2018151347A1 (fr) Micro-organisme ayant un potentiel de production de l-threonine et méthode de production de l-thréonine l'utilisant
WO2021201489A1 (fr) Vecteur recombiné pour la transformation améliorant la productivité de la glutamine, et souche l'utilisant
WO2012008810A2 (fr) Micro-organisme ayant une productivité de l-lysine améliorée et procédé de production de l-lysine l'utilisant
WO2022050527A1 (fr) Variant de corynebacterium glutamicum présentant une capacité de production de l-lysine améliorée, et procédé de production de l-lysine l'utilisant
WO2023106543A1 (fr) Variant de corynebacterium glutamicum ayant une capacité améliorée de production de l-lysine et procédé de production de l-lysine faisant appel à celui-ci
WO2022191358A1 (fr) Variant de corynebacterium glutamicum à capacité améliorée de production de l-lysine et procédé de production de l-lysine faisant appel à celui-ci
WO2022196919A1 (fr) Variant de corynébactérium glutamicum ayant une capacité de production de l-citrulline améliorée et procédé de production de l-citrulline à l'aide de celui-ci
WO2015142021A1 (fr) Micro-organisme ayant une productivité améliorée en acides l-aminés et procédé de production d'acides l-aminés les utilisant
WO2023136421A1 (fr) Mutant chez escherichia ayant une productivité de l-histidine améliorée et procédé de production de l-histidine l'utilisant
CN119082065B (zh) 鼠伤寒沙门氏菌来源的谷氨酸脱氢酶及其相关生物材料在氨基酸合成的应用
WO2022145589A1 (fr) Variant atp-prt présentant une inhibition réduite de la rétroaction provoquée par l'histidine, et souche produisant de l'histidine l'exprimant
WO2022145587A1 (fr) Variant atp-prt présentant une inhibition de rétroaction réduite par histidine, et souche productrice d'histidine l'exprimant

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17897051

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 05/12/2019)

122 Ep: pct application non-entry in european phase

Ref document number: 17897051

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载